Photopheresis (Treatment)

“Photopheresis, the process by which peripheral blood is exposed in an extracorporeal flow system to photo-activated 8-methoxypsolaren (8-MOP), is a new treatment for disorders caused by aberrant T Lymphocytes.”    



PIT Medical Systems GmbH develops technologies for the most important part of the photopheresis.

Clinical Applications

Beside the first 4 below mentioned therapy, there are many more cited in professional publications.

  • GvHD (Graft-vs.-Host-Disease After Allogenic Bone Marrow Transplantation) – Chronic & Acute
  • CTCL (Cutanous T-Cell Lymphoma)
  • Mycosis Fungoides
  • Sézary Syndrome
  • SOT Rejection (Heart, Lung, Kidney, Liver)
  • Lupus Erythematosus
  • Rheumatoid Arthritis
  • PSS (Progressive Systemic Sclerosis)
  • Atopic Dermatitis
  • Pemphigus Vulgaris
  • Crohn’s Disease
  • Colitis Ulcerosa
  • IBD (Inflammatory Bowel Disease)
  • Type 1 Diabetes
  • Epidermolysis Bullosa Acquisita
  • Erosive Oral Lichen Planus
  • Other Autoimmune Diseases

The Principle of UVA PIT Photo Immune Therapy (Photopheresis)

Photopheresis (also known as extracorporeal photopheresis or ECP) is a therapy where the patient’s blood is collected to harvest the white blood cells with an apheresis system. The collected white blood cells (buffy coat) are treated with a photosensitizer / photoactivator and subsequently are being irradiated with UVA light. This photoactivation has fundamental influence to the cell process and leads to an alteration and activation of the patient’s own immune system.

Usually existing hospital services like haematology, transfusion medicine or blood bank already have a cell separator available (mono or dual needle flow continuous or discontinuous), which allows safe and high efficient leukapheresis in a fast manner with optimal buffy coat and high concentration of monocytes.

The Photo Immune Therapy is usually done by three principal phases:

  • The collection phase where lymphocytes and mononuclear cells are collected, preferably highly concentrated with low haematocrit
  • The irradiation phase in which the buffy coat is being irradiated with UVA light (2 J/cm²) under the presence of a photoactivator (8-MOP = 8 Methoxypsoralene)
  • The reinfusion phase where the treated cells are reinfused into the patient

Side Effects

  • Due to the ex vivo treatment the side effects of the photopheresis treatment for the patient are minimal
  • The possible side effect is light sensitivity (with oral 8-MOP), which is why the patient should wear UVA protective sunglasses and avoid direct sunlight exposure for ca. 24 hours after the treatment
UVA PIT System - Online Configuration

Robust quality system

Highest quality and excellence in manufacturing are key values that guides our business.

Several thousands of treatments since 2005.

UVA PIT Photo Immune Therapy with its unique algorithm that calculates photoactivation energy based on treatment volume, haematocrit % and UVA intensity.

The Irradiation with the UVA PIT System has become a standard procedure in many treatment centers around the world and the treatment is performed on a daily basis in several institutions.

Establishing Sterile Connection with UVA PIT System

Default set up of operators makes it easy to enter the data easily and makes it to a complete solution for QMS (Quality Management System) or accredited hospitals.


3D 360° Irradiation - UVA PIT System




We are dedicated to provide fast and qualified support. 

Contact Us